Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES E SMITH

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1578516647
CMS profile
1062785
Location
CANTON, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$118.99

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $118.99 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Horizon Therapeutics plc $118.99 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES E SMITH

NPI 1578516647 · CMS profile ID 1062785

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

CANTON, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578516647?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES E SMITH, NPI 1578516647, CMS profile ID 1062785. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578516647?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CHARLES E SMITH, NPI 1578516647, CMS profile ID 1062785. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578516647?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CHARLES E SMITH, NPI 1578516647, CMS profile ID 1062785, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1578516647?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $118.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Horizon Therapeutics plc $118.9907/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937698769 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $70.77 5
PY2020 $11.82 1
PY2022 $118.99 1
PY2024 $26.38 1
PY2025 $99.39 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,813,632.49 2,042
PY2024 Principal investigator $1,429,255.26 4
PY2023 Principal investigator $105,239.00 16

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

2,042 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 12/31/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710950
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 12/31/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713174
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 12/31/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713176
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 12/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710732
Principal investigator 1 Boehringer Ingelheim International GmbH $3,276.00 12/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710750
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 12/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710772
Principal investigator 1 Boehringer Ingelheim International GmbH $3,276.00 12/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710790
Principal investigator 1 Boehringer Ingelheim International GmbH $23,611.00 12/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710794
Principal investigator 1 Boehringer Ingelheim International GmbH $3,080.00 12/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710812
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 12/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710846
Principal investigator 1 Boehringer Ingelheim International GmbH $2,977.80 12/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710854
Principal investigator 1 Boehringer Ingelheim International GmbH $1,008.70 12/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710870
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 12/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710920
Principal investigator 1 Boehringer Ingelheim International GmbH $843.50 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709712
Principal investigator 1 Boehringer Ingelheim International GmbH $843.50 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709734
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709764
Principal investigator 1 Boehringer Ingelheim International GmbH $2,349.20 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709766
Principal investigator 1 Boehringer Ingelheim International GmbH $3,549.00 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709770
Principal investigator 1 Boehringer Ingelheim International GmbH $2,349.20 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709780
Principal investigator 1 Boehringer Ingelheim International GmbH $3,063.20 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709784
Principal investigator 1 Boehringer Ingelheim International GmbH $3,196.20 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709788
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709800
Principal investigator 1 Boehringer Ingelheim International GmbH $843.50 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709806
Principal investigator 1 Boehringer Ingelheim International GmbH $2,882.60 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709814
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709820
Principal investigator 1 Boehringer Ingelheim International GmbH $24,771.60 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709822
Principal investigator 1 Boehringer Ingelheim International GmbH $843.50 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709826
Principal investigator 1 Boehringer Ingelheim International GmbH $2,882.60 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709834
Principal investigator 1 Boehringer Ingelheim International GmbH $2,349.20 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709836
Principal investigator 1 Boehringer Ingelheim International GmbH $2,349.20 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709838
Principal investigator 1 Boehringer Ingelheim International GmbH $2,349.20 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709852
Principal investigator 1 Boehringer Ingelheim International GmbH $3,063.20 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709880
Principal investigator 1 Boehringer Ingelheim International GmbH $2,984.80 12/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709886
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 12/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710736
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 12/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710804
Principal investigator 1 Boehringer Ingelheim International GmbH $3,276.00 12/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710822
Principal investigator 1 Boehringer Ingelheim International GmbH $3,080.00 12/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710838
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 12/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710860
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 12/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710896
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 12/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710914
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 12/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710934
Principal investigator 1 Boehringer Ingelheim International GmbH $2,977.80 12/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710940
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709870
Principal investigator 1 Boehringer Ingelheim International GmbH $125.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709872
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713080
Principal investigator 1 Boehringer Ingelheim International GmbH $154.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713088
Principal investigator 1 Boehringer Ingelheim International GmbH $964.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713090
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713092
Principal investigator 1 Boehringer Ingelheim International GmbH $182.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713094
Principal investigator 1 Boehringer Ingelheim International GmbH $46.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713096
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713098
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713100
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713102
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713104
Principal investigator 1 Boehringer Ingelheim International GmbH $77.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713106
Principal investigator 1 Boehringer Ingelheim International GmbH $482.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713108
Principal investigator 1 Boehringer Ingelheim International GmbH $1,722.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713110
Principal investigator 1 Boehringer Ingelheim International GmbH $1,722.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713112
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713114
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713116
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713118
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713120
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713122
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713124
Principal investigator 1 Boehringer Ingelheim International GmbH $4,078.00 12/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713126
Principal investigator 1 Boehringer Ingelheim International GmbH $1,237.60 12/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709714
Principal investigator 1 Boehringer Ingelheim International GmbH $786.80 12/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709718
Principal investigator 1 Boehringer Ingelheim International GmbH $669.20 12/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709740
Principal investigator 1 Boehringer Ingelheim International GmbH $2,520.00 12/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709748
Principal investigator 1 Boehringer Ingelheim International GmbH $2,382.80 12/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709754
Principal investigator 1 Boehringer Ingelheim International GmbH $805.00 12/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709876
Principal investigator 1 Boehringer Ingelheim International GmbH $743.40 12/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709878
Principal investigator 1 Boehringer Ingelheim International GmbH $882.00 12/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709890
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 12/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220711012
Principal investigator 1 Boehringer Ingelheim International GmbH $219.78 12/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220711014
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 12/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220711016
Principal investigator 1 Boehringer Ingelheim International GmbH $2.00 12/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220711018
Principal investigator 1 Boehringer Ingelheim International GmbH $100.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709716
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709720
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709722
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709724
Principal investigator 1 Boehringer Ingelheim International GmbH $46.20 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709726
Principal investigator 1 Boehringer Ingelheim International GmbH $4,306.40 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709728
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709730
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709732
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709736
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709738
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709742
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709744
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709746
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709750
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709752
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709756
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709758
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709760
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709762
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709768
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709772
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709774
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709776
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709778
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709782
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709786
Principal investigator 1 Boehringer Ingelheim International GmbH $61.60 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709790
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709792
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709794
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709796
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709798
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709802
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709804
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709808
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709810
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709812
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709816
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709818
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709824
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709828
Principal investigator 1 Boehringer Ingelheim International GmbH $100.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709830
Principal investigator 1 Boehringer Ingelheim International GmbH $271.60 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709832
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709840
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709842
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709844
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709846
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709848
Principal investigator 1 Boehringer Ingelheim International GmbH $98.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709850
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709854
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709856
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709858
Principal investigator 1 Boehringer Ingelheim International GmbH $100.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709860
Principal investigator 1 Boehringer Ingelheim International GmbH $650.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709862
Principal investigator 1 Boehringer Ingelheim International GmbH $4.28 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709864
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709866
Principal investigator 1 Boehringer Ingelheim International GmbH $5.96 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709868
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709874
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709882
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709884
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 12/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709888
Principal investigator 1 Boehringer Ingelheim International GmbH $655.20 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710724
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710738
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710748
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710754
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710756
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710758
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710760
Principal investigator 1 Boehringer Ingelheim International GmbH $74.20 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710762
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710770
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710784
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710800
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710818
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710832
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710834
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710842
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710848
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710856
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710866
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710868
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710872
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710874
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710884
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710898
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710918
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710922
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710926
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710946
Principal investigator 1 Boehringer Ingelheim International GmbH $74.20 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710954
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710968
Principal investigator 1 Boehringer Ingelheim International GmbH $610.40 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710970
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710990
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710992
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710994
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710996
Principal investigator 1 Boehringer Ingelheim International GmbH $271.60 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710726
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710728
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710730
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710734
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710740
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710742
Principal investigator 1 Boehringer Ingelheim International GmbH $1,050.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710744
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710746
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710752
Principal investigator 1 Boehringer Ingelheim International GmbH $271.60 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710764
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710766
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710768
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710774
Principal investigator 1 Boehringer Ingelheim International GmbH $74.20 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710776
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710778
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710780
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710782
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710786
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710788
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710792
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710796
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710798
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710802
Principal investigator 1 Boehringer Ingelheim International GmbH $74.20 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710806
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710808
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710810
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710814
Principal investigator 1 Boehringer Ingelheim International GmbH $7,630.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710816
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710820
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710824
Principal investigator 1 Boehringer Ingelheim International GmbH $560.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710826
Principal investigator 1 Boehringer Ingelheim International GmbH $859.60 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710828
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710830
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710836
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710840
Principal investigator 1 Boehringer Ingelheim International GmbH $176.40 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710844
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710850
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710852
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710858
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710862
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710864
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710876
Principal investigator 1 Boehringer Ingelheim International GmbH $100.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710878
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710880
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710882
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710886
Principal investigator 1 Boehringer Ingelheim International GmbH $100.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710888
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710890
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710892
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710894
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710900
Principal investigator 1 Boehringer Ingelheim International GmbH $176.40 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710902
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710904
Principal investigator 1 Boehringer Ingelheim International GmbH $539.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710906
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710908
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710910
Principal investigator 1 Boehringer Ingelheim International GmbH $61.60 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710912
Principal investigator 1 Boehringer Ingelheim International GmbH $1,050.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710916
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710924
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710928
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710930
Principal investigator 1 Boehringer Ingelheim International GmbH $74.20 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710932
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710936
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710938
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710942
Principal investigator 1 Boehringer Ingelheim International GmbH $98.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710944
Principal investigator 1 Boehringer Ingelheim International GmbH $1,050.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710948
Principal investigator 1 Boehringer Ingelheim International GmbH $859.60 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710952
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710956
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710958
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710960
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710962
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710964
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710966
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710972
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710974
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710976
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710978
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710980
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710982
Principal investigator 1 Boehringer Ingelheim International GmbH $74.20 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710984
Principal investigator 1 Boehringer Ingelheim International GmbH $74.20 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710986
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710988
Principal investigator 1 Boehringer Ingelheim International GmbH $61.60 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710998
Principal investigator 1 Boehringer Ingelheim International GmbH $98.00 12/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220711000
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220711028
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713068
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713070
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713072
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713074
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713076
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713078
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713082
Principal investigator 1 Boehringer Ingelheim International GmbH $4,200.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713084
Principal investigator 1 Boehringer Ingelheim International GmbH $560.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713086
Principal investigator 1 Boehringer Ingelheim International GmbH $77.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713128
Principal investigator 1 Boehringer Ingelheim International GmbH $482.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713130
Principal investigator 1 Boehringer Ingelheim International GmbH $182.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713132
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713134
Principal investigator 1 Boehringer Ingelheim International GmbH $46.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713136
Principal investigator 1 Boehringer Ingelheim International GmbH $154.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713138
Principal investigator 1 Boehringer Ingelheim International GmbH $964.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713140
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713142
Principal investigator 1 Boehringer Ingelheim International GmbH $77.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713144
Principal investigator 1 Boehringer Ingelheim International GmbH $964.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713146
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713148
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713150
Principal investigator 1 Boehringer Ingelheim International GmbH $4,480.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713152
Principal investigator 1 Boehringer Ingelheim International GmbH $19,112.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713154
Principal investigator 1 Boehringer Ingelheim International GmbH $77.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713156
Principal investigator 1 Boehringer Ingelheim International GmbH $482.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713158
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713160
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713162
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 12/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713164
Principal investigator 1 Boehringer Ingelheim International GmbH $1,008.70 11/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710668
Principal investigator 1 Boehringer Ingelheim International GmbH $3,080.00 11/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710670
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 11/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710680
Principal investigator 1 Boehringer Ingelheim International GmbH $3,595.20 11/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710690
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 11/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710692
Principal investigator 1 Boehringer Ingelheim International GmbH $23,611.00 11/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710694
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 11/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710698
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 11/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710704
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 11/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710706
Principal investigator 1 Boehringer Ingelheim International GmbH $3,647.00 11/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710708
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 11/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710710
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 11/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710718
Principal investigator 1 Boehringer Ingelheim International GmbH $3,276.00 11/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710720
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 11/24/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709704
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 11/24/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709708
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 11/21/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709706
Principal investigator 1 Boehringer Ingelheim International GmbH $65.00 11/21/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709710
Principal investigator 1 Boehringer Ingelheim International GmbH $233.20 11/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709896
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 11/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709898
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 11/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220711030
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 11/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220711032
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.20 11/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710672
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 11/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710674
Principal investigator 1 Boehringer Ingelheim International GmbH $539.00 11/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710676
Principal investigator 1 Boehringer Ingelheim International GmbH $7,630.00 11/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710682
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 11/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710684
Principal investigator 1 Boehringer Ingelheim International GmbH $539.00 11/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710686
Principal investigator 1 Boehringer Ingelheim International GmbH $859.60 11/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710688
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 11/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710696
Principal investigator 1 Boehringer Ingelheim International GmbH $8,680.00 11/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710700
Principal investigator 1 Boehringer Ingelheim International GmbH $6,221.60 11/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710702
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 11/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710714
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 11/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710716
Principal investigator 1 Boehringer Ingelheim International GmbH $176.40 11/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710722
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 11/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710678
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 11/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710712
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 11/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713056
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 11/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713058
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 11/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713060
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 11/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713062
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 11/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713064
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 11/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713066
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 11/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220711020
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 11/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220711022
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220711024
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 11/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220711026
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713044
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713046
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713048
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713050
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713052
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713054
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 10/31/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713166
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 10/31/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713168
Principal investigator 1 Boehringer Ingelheim International GmbH $10,070.20 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709624
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709626
Principal investigator 1 Boehringer Ingelheim International GmbH $539.00 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709628
Principal investigator 1 Boehringer Ingelheim International GmbH $539.00 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709634
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709636
Principal investigator 1 Boehringer Ingelheim International GmbH $1,747.20 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709638
Principal investigator 1 Boehringer Ingelheim International GmbH $697.20 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709640
Principal investigator 1 Boehringer Ingelheim International GmbH $599.20 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709642
Principal investigator 1 Boehringer Ingelheim International GmbH $3,812.20 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709644
Principal investigator 1 Boehringer Ingelheim International GmbH $282.80 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709646
Principal investigator 1 Boehringer Ingelheim International GmbH $1,540.00 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709650
Principal investigator 1 Boehringer Ingelheim International GmbH $8,260.00 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709662
Principal investigator 1 Boehringer Ingelheim International GmbH $879.20 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709668
Principal investigator 1 Boehringer Ingelheim International GmbH $599.20 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709672
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709676
Principal investigator 1 Boehringer Ingelheim International GmbH $1,232.00 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709682
Principal investigator 1 Boehringer Ingelheim International GmbH $784.00 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709684
Principal investigator 1 Boehringer Ingelheim International GmbH $2,937.20 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709686
Principal investigator 1 Boehringer Ingelheim International GmbH $14,560.20 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709688
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709690
Principal investigator 1 Boehringer Ingelheim International GmbH $743.40 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709694
Principal investigator 1 Boehringer Ingelheim International GmbH $1,740.20 10/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709702
Principal investigator 1 Boehringer Ingelheim International GmbH $18,258.80 10/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710602
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 10/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713170
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 10/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713172
Principal investigator 1 Boehringer Ingelheim International GmbH $3,549.00 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709622
Principal investigator 1 Boehringer Ingelheim International GmbH $3,063.20 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709632
Principal investigator 1 Boehringer Ingelheim International GmbH $2,882.60 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709648
Principal investigator 1 Boehringer Ingelheim International GmbH $3,196.20 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709652
Principal investigator 1 Boehringer Ingelheim International GmbH $2,349.20 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709654
Principal investigator 1 Boehringer Ingelheim International GmbH $3,549.00 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709656
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709658
Principal investigator 1 Boehringer Ingelheim International GmbH $3,196.20 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709664
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709670
Principal investigator 1 Boehringer Ingelheim International GmbH $24,941.00 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709674
Principal investigator 1 Boehringer Ingelheim International GmbH $5,115.60 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709678
Principal investigator 1 Boehringer Ingelheim International GmbH $2,349.20 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709680
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709700
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709892
Principal investigator 1 Boehringer Ingelheim International GmbH $504.40 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709894
Principal investigator 1 Boehringer Ingelheim International GmbH $2,977.80 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710560
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710566
Principal investigator 1 Boehringer Ingelheim International GmbH $5,171.60 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710568
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710572
Principal investigator 1 Boehringer Ingelheim International GmbH $3,080.00 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710582
Principal investigator 1 Boehringer Ingelheim International GmbH $2,977.80 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710584
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710592
Principal investigator 1 Boehringer Ingelheim International GmbH $3,276.00 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710596
Principal investigator 1 Boehringer Ingelheim International GmbH $3,080.00 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710618
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710620
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710636
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710664
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710666
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220711002
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220711004
Principal investigator 1 Boehringer Ingelheim International GmbH $511.00 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220711006
Principal investigator 1 Boehringer Ingelheim International GmbH $504.40 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220711008
Principal investigator 1 Boehringer Ingelheim International GmbH $4.00 10/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220711010
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 10/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709660
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 10/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709666
Principal investigator 1 Boehringer Ingelheim International GmbH $490.00 10/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712918
Principal investigator 1 Boehringer Ingelheim International GmbH $77.00 10/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712926
Principal investigator 1 Boehringer Ingelheim International GmbH $182.00 10/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713034
Principal investigator 1 Boehringer Ingelheim International GmbH $482.00 10/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713036
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 10/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709630
Principal investigator 1 Boehringer Ingelheim International GmbH $6,118.00 10/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709692
Principal investigator 1 Boehringer Ingelheim International GmbH $5,115.60 10/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709696
Principal investigator 1 Boehringer Ingelheim International GmbH $6,118.00 10/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709698
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 10/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710658
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 10/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712908
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 10/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712910
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712912
Principal investigator 1 Boehringer Ingelheim International GmbH $2,940.00 10/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712914
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 10/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712916
Principal investigator 1 Boehringer Ingelheim International GmbH $385.00 10/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712924
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 10/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713012
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 10/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713014
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 10/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713016
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 10/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713018
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 10/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713020
Principal investigator 1 Boehringer Ingelheim International GmbH $4,480.00 10/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713022
Principal investigator 1 Boehringer Ingelheim International GmbH $1,928.00 10/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713024
Principal investigator 1 Boehringer Ingelheim International GmbH $8,680.00 10/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713026
Principal investigator 1 Boehringer Ingelheim International GmbH $8,960.00 10/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713028
Principal investigator 1 Boehringer Ingelheim International GmbH $17,360.00 10/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713030
Principal investigator 1 Boehringer Ingelheim International GmbH $182.00 10/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713032
Principal investigator 1 Boehringer Ingelheim International GmbH $60.00 10/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713038
Principal investigator 1 Boehringer Ingelheim International GmbH $750.00 10/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713042
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712960
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712962
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712964
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712966
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712968
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712970
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712972
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712974
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712976
Principal investigator 1 Boehringer Ingelheim International GmbH $136.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712978
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712980
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712982
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712984
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712986
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712988
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712990
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712992
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712994
Principal investigator 1 Boehringer Ingelheim International GmbH $2,379.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712996
Principal investigator 1 Boehringer Ingelheim International GmbH $4,078.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712998
Principal investigator 1 Boehringer Ingelheim International GmbH $4,078.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713000
Principal investigator 1 Boehringer Ingelheim International GmbH $4,078.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713002
Principal investigator 1 Boehringer Ingelheim International GmbH $136.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713004
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713006
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713008
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 10/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713010
Principal investigator 1 Boehringer Ingelheim International GmbH $100.80 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710544
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710546
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710548
Principal investigator 1 Boehringer Ingelheim International GmbH $981.40 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710550
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710552
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710554
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710556
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710558
Principal investigator 1 Boehringer Ingelheim International GmbH $310.80 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710562
Principal investigator 1 Boehringer Ingelheim International GmbH $280.00 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710564
Principal investigator 1 Boehringer Ingelheim International GmbH $280.00 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710570
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710574
Principal investigator 1 Boehringer Ingelheim International GmbH $148.40 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710576
Principal investigator 1 Boehringer Ingelheim International GmbH $1,540.00 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710578
Principal investigator 1 Boehringer Ingelheim International GmbH $282.80 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710580
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710586
Principal investigator 1 Boehringer Ingelheim International GmbH $793.80 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710588
Principal investigator 1 Boehringer Ingelheim International GmbH $407.40 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710590
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710594
Principal investigator 1 Boehringer Ingelheim International GmbH $1,527.40 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710598
Principal investigator 1 Boehringer Ingelheim International GmbH $8,260.00 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710600
Principal investigator 1 Boehringer Ingelheim International GmbH $540.40 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710604
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710606
Principal investigator 1 Boehringer Ingelheim International GmbH $407.40 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710608
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710610
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710612
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710614
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710616
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710622
Principal investigator 1 Boehringer Ingelheim International GmbH $280.00 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710624
Principal investigator 1 Boehringer Ingelheim International GmbH $539.00 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710626
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710628
Principal investigator 1 Boehringer Ingelheim International GmbH $280.00 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710630
Principal investigator 1 Boehringer Ingelheim International GmbH $1,540.00 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710632
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710634
Principal investigator 1 Boehringer Ingelheim International GmbH $222.60 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710638
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710640
Principal investigator 1 Boehringer Ingelheim International GmbH $98.00 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710642
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710644
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710646
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710648
Principal investigator 1 Boehringer Ingelheim International GmbH $610.40 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710650
Principal investigator 1 Boehringer Ingelheim International GmbH $543.20 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710652
Principal investigator 1 Boehringer Ingelheim International GmbH $271.60 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710654
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710656
Principal investigator 1 Boehringer Ingelheim International GmbH $466.20 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710660
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 10/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710662
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712900
Principal investigator 1 Boehringer Ingelheim International GmbH $1,190.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712902
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712904
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712906
Principal investigator 1 Boehringer Ingelheim International GmbH $77.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712920
Principal investigator 1 Boehringer Ingelheim International GmbH $154.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712922
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712928
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712930
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712932
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712934
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712936
Principal investigator 1 Boehringer Ingelheim International GmbH $315.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712938
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712940
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712942
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712944
Principal investigator 1 Boehringer Ingelheim International GmbH $482.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712946
Principal investigator 1 Boehringer Ingelheim International GmbH $964.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712948
Principal investigator 1 Boehringer Ingelheim International GmbH $4,480.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712950
Principal investigator 1 Boehringer Ingelheim International GmbH $4,480.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712952
Principal investigator 1 Boehringer Ingelheim International GmbH $17,360.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712954
Principal investigator 1 Boehringer Ingelheim International GmbH $8,680.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712956
Principal investigator 1 Boehringer Ingelheim International GmbH $182.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712958
Principal investigator 1 Boehringer Ingelheim International GmbH $750.00 10/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220713040
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712888
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712890
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712892
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712894
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712896
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712898
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 09/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712766
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 09/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712846
Principal investigator 1 Boehringer Ingelheim International GmbH $4,250.16 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709620
Principal investigator 1 Boehringer Ingelheim International GmbH $2,977.80 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710192
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710210
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710216
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710236
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710248
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710250
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710252
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710254
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710266
Principal investigator 1 Boehringer Ingelheim International GmbH $3,080.00 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710268
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710270
Principal investigator 1 Boehringer Ingelheim International GmbH $2,977.80 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710272
Principal investigator 1 Boehringer Ingelheim International GmbH $3,595.20 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710276
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710284
Principal investigator 1 Boehringer Ingelheim International GmbH $2,977.80 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710292
Principal investigator 1 Boehringer Ingelheim International GmbH $3,080.00 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710300
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710324
Principal investigator 1 Boehringer Ingelheim International GmbH $3,080.00 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710336
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710348
Principal investigator 1 Boehringer Ingelheim International GmbH $2,977.80 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710350
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710356
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710364
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710370
Principal investigator 1 Boehringer Ingelheim International GmbH $2,977.80 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710372
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710384
Principal investigator 1 Boehringer Ingelheim International GmbH $2,977.80 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710386
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710388
Principal investigator 1 Boehringer Ingelheim International GmbH $5,171.60 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710394
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710406
Principal investigator 1 Boehringer Ingelheim International GmbH $3,595.20 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710408
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710424
Principal investigator 1 Boehringer Ingelheim International GmbH $2,977.80 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710428
Principal investigator 1 Boehringer Ingelheim International GmbH $5,171.60 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710434
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710452
Principal investigator 1 Boehringer Ingelheim International GmbH $3,080.00 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710460
Principal investigator 1 Boehringer Ingelheim International GmbH $3,080.00 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710462
Principal investigator 1 Boehringer Ingelheim International GmbH $2,977.80 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710476
Principal investigator 1 Boehringer Ingelheim International GmbH $3,080.00 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710490
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710498
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710504
Principal investigator 1 Boehringer Ingelheim International GmbH $2,444.40 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710534
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 09/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710536
Principal investigator 1 Boehringer Ingelheim International GmbH $4,250.16 09/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710414
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 09/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712814
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 09/24/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709614
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 09/24/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709616
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 09/24/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709618
Principal investigator 1 Boehringer Ingelheim International GmbH $279.72 09/24/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710178
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 09/24/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710180
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 09/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712700
Principal investigator 1 Boehringer Ingelheim International GmbH $154.00 09/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712744
Principal investigator 1 Boehringer Ingelheim International GmbH $840.00 09/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712800
Principal investigator 1 Boehringer Ingelheim International GmbH $964.00 09/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712812
Principal investigator 1 Boehringer Ingelheim International GmbH $5,000.00 09/17/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712870
Principal investigator 1 Boehringer Ingelheim International GmbH $6,769.00 09/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710390
Principal investigator 1 Boehringer Ingelheim International GmbH $100.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710182
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710184
Principal investigator 1 Boehringer Ingelheim International GmbH $222.60 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710186
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710188
Principal investigator 1 Boehringer Ingelheim International GmbH $539.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710190
Principal investigator 1 Boehringer Ingelheim International GmbH $407.40 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710194
Principal investigator 1 Boehringer Ingelheim International GmbH $518.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710196
Principal investigator 1 Boehringer Ingelheim International GmbH $407.40 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710198
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710200
Principal investigator 1 Boehringer Ingelheim International GmbH $280.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710202
Principal investigator 1 Boehringer Ingelheim International GmbH $74.20 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710204
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710208
Principal investigator 1 Boehringer Ingelheim International GmbH $271.60 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710212
Principal investigator 1 Boehringer Ingelheim International GmbH $280.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710214
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710218
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710220
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710222
Principal investigator 1 Boehringer Ingelheim International GmbH $74.20 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710224
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710226
Principal investigator 1 Boehringer Ingelheim International GmbH $61.60 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710230
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710232
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710234
Principal investigator 1 Boehringer Ingelheim International GmbH $148.40 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710238
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710240
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710242
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710244
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710256
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710258
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710260
Principal investigator 1 Boehringer Ingelheim International GmbH $98.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710262
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710274
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710278
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710280
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710282
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710286
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710288
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710294
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710296
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710298
Principal investigator 1 Boehringer Ingelheim International GmbH $61.60 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710304
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710306
Principal investigator 1 Boehringer Ingelheim International GmbH $271.60 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710308
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710310
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710312
Principal investigator 1 Boehringer Ingelheim International GmbH $292.60 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710314
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710318
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710320
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710322
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710326
Principal investigator 1 Boehringer Ingelheim International GmbH $74.20 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710328
Principal investigator 1 Boehringer Ingelheim International GmbH $100.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710330
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710332
Principal investigator 1 Boehringer Ingelheim International GmbH $148.40 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710334
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710340
Principal investigator 1 Boehringer Ingelheim International GmbH $397.60 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710342
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710344
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710346
Principal investigator 1 Boehringer Ingelheim International GmbH $100.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710354
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710358
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710360
Principal investigator 1 Boehringer Ingelheim International GmbH $271.60 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710362
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710366
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710368
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710374
Principal investigator 1 Boehringer Ingelheim International GmbH $74.20 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710376
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710378
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710380
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710382
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710392
Principal investigator 1 Boehringer Ingelheim International GmbH $98.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710396
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710404
Principal investigator 1 Boehringer Ingelheim International GmbH $98.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710410
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710412
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710416
Principal investigator 1 Boehringer Ingelheim International GmbH $61.60 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710420
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710426
Principal investigator 1 Boehringer Ingelheim International GmbH $148.40 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710430
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710432
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710436
Principal investigator 1 Boehringer Ingelheim International GmbH $280.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710438
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710440
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710442
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710444
Principal investigator 1 Boehringer Ingelheim International GmbH $430.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710446
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710448
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710450
Principal investigator 1 Boehringer Ingelheim International GmbH $271.60 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710454
Principal investigator 1 Boehringer Ingelheim International GmbH $407.40 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710456
Principal investigator 1 Boehringer Ingelheim International GmbH $100.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710458
Principal investigator 1 Boehringer Ingelheim International GmbH $407.40 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710464
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710468
Principal investigator 1 Boehringer Ingelheim International GmbH $407.40 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710470
Principal investigator 1 Boehringer Ingelheim International GmbH $148.40 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710472
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710474
Principal investigator 1 Boehringer Ingelheim International GmbH $100.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710478
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710480
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710482
Principal investigator 1 Boehringer Ingelheim International GmbH $543.20 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710484
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710486
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710488
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710492
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710494
Principal investigator 1 Boehringer Ingelheim International GmbH $407.40 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710496
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710500
Principal investigator 1 Boehringer Ingelheim International GmbH $61.60 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710502
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710506
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710508
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710510
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710512
Principal investigator 1 Boehringer Ingelheim International GmbH $98.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710514
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710516
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710518
Principal investigator 1 Boehringer Ingelheim International GmbH $61.60 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710520
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710522
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710524
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710526
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710528
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710530
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710532
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710538
Principal investigator 1 Boehringer Ingelheim International GmbH $98.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710540
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 09/08/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710542
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710338
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710398
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710400
Principal investigator 1 Boehringer Ingelheim International GmbH $1,036.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710418
Principal investigator 1 Boehringer Ingelheim International GmbH $120.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712692
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712694
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712696
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712698
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712704
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712706
Principal investigator 1 Boehringer Ingelheim International GmbH $336.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712708
Principal investigator 1 Boehringer Ingelheim International GmbH $546.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712710
Principal investigator 1 Boehringer Ingelheim International GmbH $336.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712712
Principal investigator 1 Boehringer Ingelheim International GmbH $17,360.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712714
Principal investigator 1 Boehringer Ingelheim International GmbH $182.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712716
Principal investigator 1 Boehringer Ingelheim International GmbH $1,446.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712718
Principal investigator 1 Boehringer Ingelheim International GmbH $8,680.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712720
Principal investigator 1 Boehringer Ingelheim International GmbH $17,360.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712722
Principal investigator 1 Boehringer Ingelheim International GmbH $17,360.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712724
Principal investigator 1 Boehringer Ingelheim International GmbH $182.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712726
Principal investigator 1 Boehringer Ingelheim International GmbH $546.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712728
Principal investigator 1 Boehringer Ingelheim International GmbH $546.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712730
Principal investigator 1 Boehringer Ingelheim International GmbH $308.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712732
Principal investigator 1 Boehringer Ingelheim International GmbH $154.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712734
Principal investigator 1 Boehringer Ingelheim International GmbH $77.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712736
Principal investigator 1 Boehringer Ingelheim International GmbH $77.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712738
Principal investigator 1 Boehringer Ingelheim International GmbH $462.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712740
Principal investigator 1 Boehringer Ingelheim International GmbH $385.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712742
Principal investigator 1 Boehringer Ingelheim International GmbH $12,180.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712746
Principal investigator 1 Boehringer Ingelheim International GmbH $3,330.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712748
Principal investigator 1 Boehringer Ingelheim International GmbH $1,190.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712750
Principal investigator 1 Boehringer Ingelheim International GmbH $910.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712752
Principal investigator 1 Boehringer Ingelheim International GmbH $2,660.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712754
Principal investigator 1 Boehringer Ingelheim International GmbH $1,190.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712756
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712758
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712760
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712762
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712764
Principal investigator 1 Boehringer Ingelheim International GmbH $1,928.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712768
Principal investigator 1 Boehringer Ingelheim International GmbH $546.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712770
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712772
Principal investigator 1 Boehringer Ingelheim International GmbH $482.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712774
Principal investigator 1 Boehringer Ingelheim International GmbH $101.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712776
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712778
Principal investigator 1 Boehringer Ingelheim International GmbH $482.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712780
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712782
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712784
Principal investigator 1 Boehringer Ingelheim International GmbH $2,892.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712786
Principal investigator 1 Boehringer Ingelheim International GmbH $964.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712788
Principal investigator 1 Boehringer Ingelheim International GmbH $4,480.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712790
Principal investigator 1 Boehringer Ingelheim International GmbH $4,480.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712792
Principal investigator 1 Boehringer Ingelheim International GmbH $672.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712794
Principal investigator 1 Boehringer Ingelheim International GmbH $8,960.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712796
Principal investigator 1 Boehringer Ingelheim International GmbH $8,960.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712798
Principal investigator 1 Boehringer Ingelheim International GmbH $315.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712802
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712804
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712806
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712808
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712810
Principal investigator 1 Boehringer Ingelheim International GmbH $2,170.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712816
Principal investigator 1 Boehringer Ingelheim International GmbH $2,379.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712818
Principal investigator 1 Boehringer Ingelheim International GmbH $2,379.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712820
Principal investigator 1 Boehringer Ingelheim International GmbH $2,379.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712822
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712824
Principal investigator 1 Boehringer Ingelheim International GmbH $136.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712826
Principal investigator 1 Boehringer Ingelheim International GmbH $1,687.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712828
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712830
Principal investigator 1 Boehringer Ingelheim International GmbH $2,663.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712832
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712834
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712836
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712838
Principal investigator 1 Boehringer Ingelheim International GmbH $2,379.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712840
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712842
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712844
Principal investigator 1 Boehringer Ingelheim International GmbH $1,582.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712848
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712850
Principal investigator 1 Boehringer Ingelheim International GmbH $1,687.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712852
Principal investigator 1 Boehringer Ingelheim International GmbH $1,687.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712854
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712856
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712858
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712860
Principal investigator 1 Boehringer Ingelheim International GmbH $2,379.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712862
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 09/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712864
Principal investigator 1 Boehringer Ingelheim International GmbH $3,595.20 09/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710206
Principal investigator 1 Boehringer Ingelheim International GmbH $38,190.60 09/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710228
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 09/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710246
Principal investigator 1 Boehringer Ingelheim International GmbH $23,611.00 09/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710264
Principal investigator 1 Boehringer Ingelheim International GmbH $3,595.20 09/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710290
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 09/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710302
Principal investigator 1 Boehringer Ingelheim International GmbH $8,377.60 09/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710316
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 09/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710352
Principal investigator 1 Boehringer Ingelheim International GmbH $3,595.20 09/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710402
Principal investigator 1 Boehringer Ingelheim International GmbH $3,595.20 09/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710422
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 09/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710466
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712510
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712512
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712514
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712516
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712518
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712520
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 08/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712690
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/29/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712702
Principal investigator 1 Boehringer Ingelheim International GmbH $999.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709606
Principal investigator 1 Boehringer Ingelheim International GmbH $1,277.50 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709608
Principal investigator 1 Boehringer Ingelheim International GmbH $504.40 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709610
Principal investigator 1 Boehringer Ingelheim International GmbH $8.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709612
Principal investigator 1 Boehringer Ingelheim International GmbH $759.24 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710170
Principal investigator 1 Boehringer Ingelheim International GmbH $1,058.50 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710172
Principal investigator 1 Boehringer Ingelheim International GmbH $504.40 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710174
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710176
Principal investigator 1 Boehringer Ingelheim International GmbH $2,379.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712534
Principal investigator 1 Boehringer Ingelheim International GmbH $3,921.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712536
Principal investigator 1 Boehringer Ingelheim International GmbH $3,178.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712538
Principal investigator 1 Boehringer Ingelheim International GmbH $3,178.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712540
Principal investigator 1 Boehringer Ingelheim International GmbH $3,921.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712542
Principal investigator 1 Boehringer Ingelheim International GmbH $3,178.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712544
Principal investigator 1 Boehringer Ingelheim International GmbH $3,178.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712546
Principal investigator 1 Boehringer Ingelheim International GmbH $3,178.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712548
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712550
Principal investigator 1 Boehringer Ingelheim International GmbH $3,178.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712552
Principal investigator 1 Boehringer Ingelheim International GmbH $2,379.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712554
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712556
Principal investigator 1 Boehringer Ingelheim International GmbH $2,379.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712558
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712560
Principal investigator 1 Boehringer Ingelheim International GmbH $1,687.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712562
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712564
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712566
Principal investigator 1 Boehringer Ingelheim International GmbH $3,178.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712568
Principal investigator 1 Boehringer Ingelheim International GmbH $2,379.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712570
Principal investigator 1 Boehringer Ingelheim International GmbH $3,178.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712572
Principal investigator 1 Boehringer Ingelheim International GmbH $2,379.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712574
Principal investigator 1 Boehringer Ingelheim International GmbH $3,178.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712576
Principal investigator 1 Boehringer Ingelheim International GmbH $3,178.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712578
Principal investigator 1 Boehringer Ingelheim International GmbH $2,379.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712580
Principal investigator 1 Boehringer Ingelheim International GmbH $1,687.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712582
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712584
Principal investigator 1 Boehringer Ingelheim International GmbH $1,687.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712586
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712588
Principal investigator 1 Boehringer Ingelheim International GmbH $1,687.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712590
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712592
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712594
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712596
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712598
Principal investigator 1 Boehringer Ingelheim International GmbH $2,379.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712600
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712602
Principal investigator 1 Boehringer Ingelheim International GmbH $2,379.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712604
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712606
Principal investigator 1 Boehringer Ingelheim International GmbH $1,687.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712608
Principal investigator 1 Boehringer Ingelheim International GmbH $1,687.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712610
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712612
Principal investigator 1 Boehringer Ingelheim International GmbH $1,687.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712614
Principal investigator 1 Boehringer Ingelheim International GmbH $1,687.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712616
Principal investigator 1 Boehringer Ingelheim International GmbH $3,178.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712618
Principal investigator 1 Boehringer Ingelheim International GmbH $1,687.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712620
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712622
Principal investigator 1 Boehringer Ingelheim International GmbH $1,687.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712624
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712626
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712628
Principal investigator 1 Boehringer Ingelheim International GmbH $136.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712630
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712632
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712634
Principal investigator 1 Boehringer Ingelheim International GmbH $2,379.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712636
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712638
Principal investigator 1 Boehringer Ingelheim International GmbH $1,687.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712640
Principal investigator 1 Boehringer Ingelheim International GmbH $1,687.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712642
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712644
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712646
Principal investigator 1 Boehringer Ingelheim International GmbH $1,582.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712658
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712660
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712662
Principal investigator 1 Boehringer Ingelheim International GmbH $4,638.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712664
Principal investigator 1 Boehringer Ingelheim International GmbH $1,687.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712666
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712668
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712670
Principal investigator 1 Boehringer Ingelheim International GmbH $136.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712672
Principal investigator 1 Boehringer Ingelheim International GmbH $136.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712674
Principal investigator 1 Boehringer Ingelheim International GmbH $136.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712676
Principal investigator 1 Boehringer Ingelheim International GmbH $3,921.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712678
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712880
Principal investigator 1 Boehringer Ingelheim International GmbH $427.49 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712882
Principal investigator 1 Boehringer Ingelheim International GmbH $10.26 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712884
Principal investigator 1 Boehringer Ingelheim International GmbH $40.88 08/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712886
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 08/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712648
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 08/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712650
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 08/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712652
Principal investigator 1 Boehringer Ingelheim International GmbH $4,480.00 08/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712654
Principal investigator 1 Boehringer Ingelheim International GmbH $8,680.00 08/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712656
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712680
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 08/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712682
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 08/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712684
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 08/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712686
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 08/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712688
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710058
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710060
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710062
Principal investigator 1 Boehringer Ingelheim International GmbH $271.60 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710064
Principal investigator 1 Boehringer Ingelheim International GmbH $271.60 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710066
Principal investigator 1 Boehringer Ingelheim International GmbH $539.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710068
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710070
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710072
Principal investigator 1 Boehringer Ingelheim International GmbH $539.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710074
Principal investigator 1 Boehringer Ingelheim International GmbH $271.60 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710076
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710078
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710080
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710082
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710084
Principal investigator 1 Boehringer Ingelheim International GmbH $61.60 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710086
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710088
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710090
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710092
Principal investigator 1 Boehringer Ingelheim International GmbH $100.80 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710094
Principal investigator 1 Boehringer Ingelheim International GmbH $98.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710096
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710098
Principal investigator 1 Boehringer Ingelheim International GmbH $61.60 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710102
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710104
Principal investigator 1 Boehringer Ingelheim International GmbH $1,176.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710106
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710108
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710110
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710112
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710114
Principal investigator 1 Boehringer Ingelheim International GmbH $560.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710116
Principal investigator 1 Boehringer Ingelheim International GmbH $539.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710118
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710120
Principal investigator 1 Boehringer Ingelheim International GmbH $280.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710122
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710124
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710126
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710128
Principal investigator 1 Boehringer Ingelheim International GmbH $280.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710130
Principal investigator 1 Boehringer Ingelheim International GmbH $100.80 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710132
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710134
Principal investigator 1 Boehringer Ingelheim International GmbH $1,176.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710136
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710138
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710140
Principal investigator 1 Boehringer Ingelheim International GmbH $560.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710142
Principal investigator 1 Boehringer Ingelheim International GmbH $98.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710144
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710146
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710148
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710150
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710152
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710154
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710156
Principal investigator 1 Boehringer Ingelheim International GmbH $148.40 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710158
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 08/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710160
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 08/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710100
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712498
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712500
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712502
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712504
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712506
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712508
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 07/31/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712866
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 07/31/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712868
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 07/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709600
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 07/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709602
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 07/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709604
Principal investigator 1 Boehringer Ingelheim International GmbH $233.20 07/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710162
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 07/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710164
Principal investigator 1 Boehringer Ingelheim International GmbH $511.00 07/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710166
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 07/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710168
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 07/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712872
Principal investigator 1 Boehringer Ingelheim International GmbH $610.70 07/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712874
Principal investigator 1 Boehringer Ingelheim International GmbH $5.40 07/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712876
Principal investigator 1 Boehringer Ingelheim International GmbH $58.40 07/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712878
Principal investigator 1 Boehringer Ingelheim International GmbH $693.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712258
Principal investigator 1 Boehringer Ingelheim International GmbH $385.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712260
Principal investigator 1 Boehringer Ingelheim International GmbH $385.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712262
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712264
Principal investigator 1 Boehringer Ingelheim International GmbH $154.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712266
Principal investigator 1 Boehringer Ingelheim International GmbH $26,040.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712268
Principal investigator 1 Boehringer Ingelheim International GmbH $26,040.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712270
Principal investigator 1 Boehringer Ingelheim International GmbH $13,440.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712272
Principal investigator 1 Boehringer Ingelheim International GmbH $13,440.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712274
Principal investigator 1 Boehringer Ingelheim International GmbH $8,680.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712276
Principal investigator 1 Boehringer Ingelheim International GmbH $8,680.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712278
Principal investigator 1 Boehringer Ingelheim International GmbH $8,680.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712280
Principal investigator 1 Boehringer Ingelheim International GmbH $8,680.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712282
Principal investigator 1 Boehringer Ingelheim International GmbH $4,820.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712284
Principal investigator 1 Boehringer Ingelheim International GmbH $4,480.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712294
Principal investigator 1 Boehringer Ingelheim International GmbH $4,480.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712296
Principal investigator 1 Boehringer Ingelheim International GmbH $4,480.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712298
Principal investigator 1 Boehringer Ingelheim International GmbH $4,480.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712300
Principal investigator 1 Boehringer Ingelheim International GmbH $4,480.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712302
Principal investigator 1 Boehringer Ingelheim International GmbH $3,750.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712304
Principal investigator 1 Boehringer Ingelheim International GmbH $3,750.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712306
Principal investigator 1 Boehringer Ingelheim International GmbH $2,410.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712328
Principal investigator 1 Boehringer Ingelheim International GmbH $1,446.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712342
Principal investigator 1 Boehringer Ingelheim International GmbH $1,446.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712344
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712352
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712354
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712356
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712358
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712360
Principal investigator 1 Boehringer Ingelheim International GmbH $964.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712392
Principal investigator 1 Boehringer Ingelheim International GmbH $630.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712396
Principal investigator 1 Boehringer Ingelheim International GmbH $630.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712398
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712400
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712402
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712404
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712406
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712408
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712410
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712412
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712414
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712422
Principal investigator 1 Boehringer Ingelheim International GmbH $77.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712424
Principal investigator 1 Boehringer Ingelheim International GmbH $364.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712426
Principal investigator 1 Boehringer Ingelheim International GmbH $336.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712428
Principal investigator 1 Boehringer Ingelheim International GmbH $336.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712430
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712432
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712434
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712436
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712438
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712440
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712442
Principal investigator 1 Boehringer Ingelheim International GmbH $182.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712444
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712446
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712448
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712450
Principal investigator 1 Boehringer Ingelheim International GmbH $120.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712454
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712464
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712466
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712468
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712470
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712472
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712474
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712476
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712478
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712492
Principal investigator 1 Boehringer Ingelheim International GmbH $46.00 07/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712496
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 07/24/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709584
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 07/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709586
Principal investigator 1 Boehringer Ingelheim International GmbH $77.00 07/21/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712394
Principal investigator 1 Boehringer Ingelheim International GmbH $482.00 07/21/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712416
Principal investigator 1 Boehringer Ingelheim International GmbH $60.00 07/21/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712480
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 07/21/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712490
Principal investigator 1 Boehringer Ingelheim International GmbH $46.00 07/21/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712494
Principal investigator 1 Boehringer Ingelheim International GmbH $24,941.00 07/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709588
Principal investigator 1 Boehringer Ingelheim International GmbH $32,569.60 07/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709590
Principal investigator 1 Boehringer Ingelheim International GmbH $6,052.20 07/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710052
Principal investigator 1 Boehringer Ingelheim International GmbH $6,221.60 07/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710054
Principal investigator 1 Boehringer Ingelheim International GmbH $6,498.80 07/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710056
Principal investigator 1 Boehringer Ingelheim International GmbH $4,778.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712286
Principal investigator 1 Boehringer Ingelheim International GmbH $4,778.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712288
Principal investigator 1 Boehringer Ingelheim International GmbH $4,778.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712290
Principal investigator 1 Boehringer Ingelheim International GmbH $4,778.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712292
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712308
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712310
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712312
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712314
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712316
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712318
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712320
Principal investigator 1 Boehringer Ingelheim International GmbH $2,519.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712322
Principal investigator 1 Boehringer Ingelheim International GmbH $2,519.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712324
Principal investigator 1 Boehringer Ingelheim International GmbH $2,519.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712326
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712330
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712332
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712334
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712336
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712338
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712340
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712346
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712348
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712350
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712362
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712364
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712366
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712368
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712370
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712372
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712374
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712376
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712378
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712380
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712382
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712384
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712386
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712388
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712390
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712418
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712420
Principal investigator 1 Boehringer Ingelheim International GmbH $136.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712452
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712456
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712458
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712460
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712462
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712482
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712484
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712486
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 07/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712488
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 07/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709592
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712522
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712524
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712526
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712528
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712530
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712532
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709262
Principal investigator 1 Boehringer Ingelheim International GmbH $24,771.60 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709264
Principal investigator 1 Boehringer Ingelheim International GmbH $2,882.60 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709270
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709274
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709284
Principal investigator 1 Boehringer Ingelheim International GmbH $2,882.60 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709286
Principal investigator 1 Boehringer Ingelheim International GmbH $2,349.20 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709290
Principal investigator 1 Boehringer Ingelheim International GmbH $3,600.80 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709298
Principal investigator 1 Boehringer Ingelheim International GmbH $24,771.60 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709304
Principal investigator 1 Boehringer Ingelheim International GmbH $3,063.20 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709312
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709316
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709324
Principal investigator 1 Boehringer Ingelheim International GmbH $18,011.00 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709326
Principal investigator 1 Boehringer Ingelheim International GmbH $3,600.80 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709336
Principal investigator 1 Boehringer Ingelheim International GmbH $2,882.60 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709344
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709348
Principal investigator 1 Boehringer Ingelheim International GmbH $2,349.20 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709356
Principal investigator 1 Boehringer Ingelheim International GmbH $24,771.60 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709358
Principal investigator 1 Boehringer Ingelheim International GmbH $2,349.20 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709364
Principal investigator 1 Boehringer Ingelheim International GmbH $2,882.60 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709370
Principal investigator 1 Boehringer Ingelheim International GmbH $3,600.80 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709374
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709394
Principal investigator 1 Boehringer Ingelheim International GmbH $18,011.00 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709400
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709404
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709410
Principal investigator 1 Boehringer Ingelheim International GmbH $2,882.60 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709414
Principal investigator 1 Boehringer Ingelheim International GmbH $18,011.00 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709420
Principal investigator 1 Boehringer Ingelheim International GmbH $24,941.00 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709422
Principal investigator 1 Boehringer Ingelheim International GmbH $24,771.60 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709428
Principal investigator 1 Boehringer Ingelheim International GmbH $24,941.00 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709440
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709448
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709450
Principal investigator 1 Boehringer Ingelheim International GmbH $2,349.20 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709458
Principal investigator 1 Boehringer Ingelheim International GmbH $24,941.00 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709460
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709466
Principal investigator 1 Boehringer Ingelheim International GmbH $2,882.60 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709474
Principal investigator 1 Boehringer Ingelheim International GmbH $3,600.80 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709500
Principal investigator 1 Boehringer Ingelheim International GmbH $2,349.20 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709502
Principal investigator 1 Boehringer Ingelheim International GmbH $2,882.60 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709514
Principal investigator 1 Boehringer Ingelheim International GmbH $2,349.20 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709520
Principal investigator 1 Boehringer Ingelheim International GmbH $3,063.20 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709522
Principal investigator 1 Boehringer Ingelheim International GmbH $38,190.60 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709930
Principal investigator 1 Boehringer Ingelheim International GmbH $2,977.80 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709932
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709934
Principal investigator 1 Boehringer Ingelheim International GmbH $23,611.00 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709940
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709942
Principal investigator 1 Boehringer Ingelheim International GmbH $3,647.00 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709944
Principal investigator 1 Boehringer Ingelheim International GmbH $23,611.00 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709948
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709952
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709960
Principal investigator 1 Boehringer Ingelheim International GmbH $26,737.20 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709964
Principal investigator 1 Boehringer Ingelheim International GmbH $3,647.00 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709966
Principal investigator 1 Boehringer Ingelheim International GmbH $2,977.80 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709968
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712164
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 06/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712166
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 06/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709524
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 06/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709962
Principal investigator 1 Boehringer Ingelheim International GmbH $31.67 06/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712168
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 06/24/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709582
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 06/24/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710048
Principal investigator 1 Boehringer Ingelheim International GmbH $239.76 06/24/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710050
Principal investigator 1 Boehringer Ingelheim International GmbH $1,095.00 06/24/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712254
Principal investigator 1 Boehringer Ingelheim International GmbH $13.50 06/24/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712256
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709260
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709268
Principal investigator 1 Boehringer Ingelheim International GmbH $1,363.60 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709278
Principal investigator 1 Boehringer Ingelheim International GmbH $60.20 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709280
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709282
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709292
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709308
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709310
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709318
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709320
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709328
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709334
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709338
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709340
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709354
Principal investigator 1 Boehringer Ingelheim International GmbH $40.60 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709362
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709372
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709376
Principal investigator 1 Boehringer Ingelheim International GmbH $539.00 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709382
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709384
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709392
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709396
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709398
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709418
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709432
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709434
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709436
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709438
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709446
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709452
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709454
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709470
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709476
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709478
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709480
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709482
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709484
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709486
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709488
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709490
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709504
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709506
Principal investigator 1 Boehringer Ingelheim International GmbH $539.00 06/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709510
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709258
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709266
Principal investigator 1 Boehringer Ingelheim International GmbH $271.60 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709272
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709276
Principal investigator 1 Boehringer Ingelheim International GmbH $74.20 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709288
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709294
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709296
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709300
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709302
Principal investigator 1 Boehringer Ingelheim International GmbH $20,528.20 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709306
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709314
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709322
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709330
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709332
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709342
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709346
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709350
Principal investigator 1 Boehringer Ingelheim International GmbH $40.60 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709352
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709360
Principal investigator 1 Boehringer Ingelheim International GmbH $697.20 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709366
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709368
Principal investigator 1 Boehringer Ingelheim International GmbH $72.80 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709378
Principal investigator 1 Boehringer Ingelheim International GmbH $100.80 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709380
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709386
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709388
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709390
Principal investigator 1 Boehringer Ingelheim International GmbH $291.20 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709402
Principal investigator 1 Boehringer Ingelheim International GmbH $61.60 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709406
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709408
Principal investigator 1 Boehringer Ingelheim International GmbH $280.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709412
Principal investigator 1 Boehringer Ingelheim International GmbH $407.40 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709416
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709424
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709426
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709430
Principal investigator 1 Boehringer Ingelheim International GmbH $3,463.60 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709442
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709444
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709456
Principal investigator 1 Boehringer Ingelheim International GmbH $24,771.60 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709462
Principal investigator 1 Boehringer Ingelheim International GmbH $271.60 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709464
Principal investigator 1 Boehringer Ingelheim International GmbH $98.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709468
Principal investigator 1 Boehringer Ingelheim International GmbH $98.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709472
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709492
Principal investigator 1 Boehringer Ingelheim International GmbH $16,048.20 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709494
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709496
Principal investigator 1 Boehringer Ingelheim International GmbH $162.40 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709498
Principal investigator 1 Boehringer Ingelheim International GmbH $61.60 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709508
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709512
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709516
Principal investigator 1 Boehringer Ingelheim International GmbH $1,540.00 06/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709518
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/13/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709926
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 06/13/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709928
Principal investigator 1 Boehringer Ingelheim International GmbH $271.60 06/13/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709936
Principal investigator 1 Boehringer Ingelheim International GmbH $98.00 06/13/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709938
Principal investigator 1 Boehringer Ingelheim International GmbH $61.60 06/13/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709946
Principal investigator 1 Boehringer Ingelheim International GmbH $100.80 06/13/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709950
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 06/13/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709954
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 06/13/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709956
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 06/13/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709958
Principal investigator 1 Boehringer Ingelheim International GmbH $315.00 06/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712136
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 06/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712138
Principal investigator 1 Boehringer Ingelheim International GmbH $8,960.00 06/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712140
Principal investigator 1 Boehringer Ingelheim International GmbH $17,360.00 06/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712142
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 06/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712148
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712114
Principal investigator 1 Boehringer Ingelheim International GmbH $4,778.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712116
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712118
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712120
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712122
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712124
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712126
Principal investigator 1 Boehringer Ingelheim International GmbH $2,519.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712128
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712130
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712132
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712134
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712144
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712146
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712150
Principal investigator 1 Boehringer Ingelheim International GmbH $154.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712152
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712170
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712172
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712174
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712176
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712178
Principal investigator 1 Boehringer Ingelheim International GmbH $964.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712180
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712182
Principal investigator 1 Boehringer Ingelheim International GmbH $964.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712184
Principal investigator 1 Boehringer Ingelheim International GmbH $336.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712186
Principal investigator 1 Boehringer Ingelheim International GmbH $8,960.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712188
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712190
Principal investigator 1 Boehringer Ingelheim International GmbH $17,360.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712192
Principal investigator 1 Boehringer Ingelheim International GmbH $182.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712194
Principal investigator 1 Boehringer Ingelheim International GmbH $182.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712196
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712198
Principal investigator 1 Boehringer Ingelheim International GmbH $46.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712200
Principal investigator 1 Boehringer Ingelheim International GmbH $1,722.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712202
Principal investigator 1 Boehringer Ingelheim International GmbH $136.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712204
Principal investigator 1 Boehringer Ingelheim International GmbH $2,519.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712206
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712208
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712210
Principal investigator 1 Boehringer Ingelheim International GmbH $4,778.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712212
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712214
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712216
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712218
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712220
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712222
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712224
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712226
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712228
Principal investigator 1 Boehringer Ingelheim International GmbH $2,519.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712230
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712232
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712234
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712236
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712238
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712240
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712242
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712244
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 06/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712246
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 06/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709596
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 06/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709598
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712102
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712104
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712106
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712108
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712110
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712112
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 05/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712158
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 05/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712160
Principal investigator 1 Boehringer Ingelheim International GmbH $24,941.00 05/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709526
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 05/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709534
Principal investigator 1 Boehringer Ingelheim International GmbH $2,882.60 05/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709538
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 05/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709540
Principal investigator 1 Boehringer Ingelheim International GmbH $18,011.00 05/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709552
Principal investigator 1 Boehringer Ingelheim International GmbH $1,017.10 05/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709970
Principal investigator 1 Boehringer Ingelheim International GmbH $26,737.20 05/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709972
Principal investigator 1 Boehringer Ingelheim International GmbH $23,611.00 05/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709974
Principal investigator 1 Boehringer Ingelheim International GmbH $38,190.60 05/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709988
Principal investigator 1 Boehringer Ingelheim International GmbH $3,647.00 05/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710036
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 05/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709574
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 05/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709576
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 05/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709578
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 05/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709580
Principal investigator 1 Boehringer Ingelheim International GmbH $221.54 05/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710042
Principal investigator 1 Boehringer Ingelheim International GmbH $474.50 05/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710044
Principal investigator 1 Boehringer Ingelheim International GmbH $13.00 05/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710046
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 05/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712248
Principal investigator 1 Boehringer Ingelheim International GmbH $1,008.80 05/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712250
Principal investigator 1 Boehringer Ingelheim International GmbH $5.40 05/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712252
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 05/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709528
Principal investigator 1 Boehringer Ingelheim International GmbH $539.00 05/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709530
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 05/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709532
Principal investigator 1 Boehringer Ingelheim International GmbH $1,540.00 05/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709536
Principal investigator 1 Boehringer Ingelheim International GmbH $1,540.00 05/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709542
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 05/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709544
Principal investigator 1 Boehringer Ingelheim International GmbH $1,540.00 05/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709546
Principal investigator 1 Boehringer Ingelheim International GmbH $539.00 05/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709548
Principal investigator 1 Boehringer Ingelheim International GmbH $539.00 05/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709550
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 05/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709554
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 05/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709556
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 05/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709558
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709976
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709978
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709980
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709982
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709986
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709992
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709994
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709996
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709998
Principal investigator 1 Boehringer Ingelheim International GmbH $990.50 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710000
Principal investigator 1 Boehringer Ingelheim International GmbH $763.00 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710002
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710004
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710006
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710008
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710010
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710012
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710014
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710022
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710024
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710026
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710030
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710034
Principal investigator 1 Boehringer Ingelheim International GmbH $15.84 05/22/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712162
Principal investigator 1 Boehringer Ingelheim International GmbH $539.00 05/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709984
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 05/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709990
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 05/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710016
Principal investigator 1 Boehringer Ingelheim International GmbH $539.00 05/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710018
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 05/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710020
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 05/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710028
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 05/16/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710032
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 05/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711974
Principal investigator 1 Boehringer Ingelheim International GmbH $616.00 05/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711978
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 05/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711986
Principal investigator 1 Boehringer Ingelheim International GmbH $1,928.00 05/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712078
Principal investigator 1 Boehringer Ingelheim International GmbH $840.00 05/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712080
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 05/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712082
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 05/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712084
Principal investigator 1 Boehringer Ingelheim International GmbH $4,480.00 05/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712086
Principal investigator 1 Boehringer Ingelheim International GmbH $8,680.00 05/14/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712088
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 05/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711972
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 05/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711976
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 05/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711980
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 05/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711982
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 05/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711984
Principal investigator 1 Boehringer Ingelheim International GmbH $482.00 05/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712062
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 05/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712064
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 05/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712066
Principal investigator 1 Boehringer Ingelheim International GmbH $46.00 05/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712068
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 05/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712070
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 05/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712072
Principal investigator 1 Boehringer Ingelheim International GmbH $8,960.00 05/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712074
Principal investigator 1 Boehringer Ingelheim International GmbH $17,360.00 05/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712076
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711988
Principal investigator 1 Boehringer Ingelheim International GmbH $2,519.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711990
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711992
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711994
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711996
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711998
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712000
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712002
Principal investigator 1 Boehringer Ingelheim International GmbH $136.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712004
Principal investigator 1 Boehringer Ingelheim International GmbH $4,778.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712006
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712008
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712010
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712012
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712014
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712016
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712018
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712020
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712022
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712024
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712026
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712028
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712030
Principal investigator 1 Boehringer Ingelheim International GmbH $497.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712032
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712034
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712036
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712038
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712040
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712042
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712044
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712046
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712048
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712050
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712052
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712054
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712056
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712058
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 05/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712060
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 05/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709560
Principal investigator 1 Boehringer Ingelheim International GmbH $58.00 05/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709562
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 05/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709564
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712090
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712092
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712094
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712096
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712098
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712100
Principal investigator 1 Boehringer Ingelheim International GmbH $16,048.20 04/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709192
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 04/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709198
Principal investigator 1 Boehringer Ingelheim International GmbH $64.29 04/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709200
Principal investigator 1 Boehringer Ingelheim International GmbH $195.00 04/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709202
Principal investigator 1 Boehringer Ingelheim International GmbH $24,941.00 04/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709252
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 04/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709912
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 04/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709914
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 04/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709916
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 04/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709918
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 04/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709920
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 04/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709922
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 04/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709924
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 04/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712154
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 04/30/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220712156
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709186
Principal investigator 1 Boehringer Ingelheim International GmbH $100.80 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709188
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709190
Principal investigator 1 Boehringer Ingelheim International GmbH $98.00 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709194
Principal investigator 1 Boehringer Ingelheim International GmbH $40.60 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709196
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709204
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709210
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709212
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709214
Principal investigator 1 Boehringer Ingelheim International GmbH $240.80 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709216
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709218
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709220
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709222
Principal investigator 1 Boehringer Ingelheim International GmbH $44.80 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709224
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709230
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709232
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709234
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709236
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709238
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709240
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709242
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709244
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709246
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709248
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709250
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709254
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 04/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709256
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 04/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709566
Principal investigator 1 Boehringer Ingelheim International GmbH $199.80 04/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709568
Principal investigator 1 Boehringer Ingelheim International GmbH $474.50 04/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709570
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 04/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709572
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 04/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710038
Principal investigator 1 Boehringer Ingelheim International GmbH $511.00 04/23/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220710040
Principal investigator 1 Boehringer Ingelheim International GmbH $231.00 04/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711838
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 04/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711840
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 04/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711842
Principal investigator 1 Boehringer Ingelheim International GmbH $630.00 04/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711944
Principal investigator 1 Boehringer Ingelheim International GmbH $3,750.00 04/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711946
Principal investigator 1 Boehringer Ingelheim International GmbH $13,440.00 04/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711948
Principal investigator 1 Boehringer Ingelheim International GmbH $26,040.00 04/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711950
Principal investigator 1 Boehringer Ingelheim International GmbH $735.00 04/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711952
Principal investigator 1 Boehringer Ingelheim International GmbH $3,750.00 04/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711954
Principal investigator 1 Boehringer Ingelheim International GmbH $482.00 04/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711956
Principal investigator 1 Boehringer Ingelheim International GmbH $17,920.00 04/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711958
Principal investigator 1 Boehringer Ingelheim International GmbH $280.00 04/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711960
Principal investigator 1 Boehringer Ingelheim International GmbH $26,040.00 04/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711962
Principal investigator 1 Boehringer Ingelheim International GmbH $46.00 04/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711964
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 04/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711968
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 04/18/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711970
Principal investigator 1 Boehringer Ingelheim International GmbH $60.00 04/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711834
Principal investigator 1 Boehringer Ingelheim International GmbH $308.00 04/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711836
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 04/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711938
Principal investigator 1 Boehringer Ingelheim International GmbH $964.00 04/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711940
Principal investigator 1 Boehringer Ingelheim International GmbH $280.00 04/09/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711942
Principal investigator 1 Boehringer Ingelheim International GmbH $1,722.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711844
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711846
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711848
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711850
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711852
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711854
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711856
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711858
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711860
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711862
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711864
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711866
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711868
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711870
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711872
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711874
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711876
Principal investigator 1 Boehringer Ingelheim International GmbH $497.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711878
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711880
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711882
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711884
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711886
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711888
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711890
Principal investigator 1 Boehringer Ingelheim International GmbH $4,778.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711892
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711894
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711896
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711898
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711900
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711902
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711904
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711906
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711908
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711910
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711912
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711914
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711916
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711918
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711920
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711922
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711924
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711926
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711928
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711930
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711932
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711934
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 04/04/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711936
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 04/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711826
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 04/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711828
Principal investigator 1 Boehringer Ingelheim International GmbH $4,480.00 04/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711830
Principal investigator 1 Boehringer Ingelheim International GmbH $8,680.00 04/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711832
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 04/02/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711966
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 04/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709206
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711814
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711816
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711818
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711820
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711822
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711824
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 03/31/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711604
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 03/31/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711606
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711582
Principal investigator 1 Boehringer Ingelheim International GmbH $462.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711588
Principal investigator 1 Boehringer Ingelheim International GmbH $462.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711590
Principal investigator 1 Boehringer Ingelheim International GmbH $308.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711592
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711610
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711612
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711614
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711616
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711618
Principal investigator 1 Boehringer Ingelheim International GmbH $2,410.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711756
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711758
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711760
Principal investigator 1 Boehringer Ingelheim International GmbH $4,480.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711762
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711764
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711766
Principal investigator 1 Boehringer Ingelheim International GmbH $8,680.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711768
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711770
Principal investigator 1 Boehringer Ingelheim International GmbH $2,410.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711772
Principal investigator 1 Boehringer Ingelheim International GmbH $840.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711774
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711776
Principal investigator 1 Boehringer Ingelheim International GmbH $964.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711778
Principal investigator 1 Boehringer Ingelheim International GmbH $560.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711780
Principal investigator 1 Boehringer Ingelheim International GmbH $60.00 03/26/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711782
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 03/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709182
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 03/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709184
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 03/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709908
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 03/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709910
Principal investigator 1 Boehringer Ingelheim International GmbH $233.20 03/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711792
Principal investigator 1 Boehringer Ingelheim International GmbH $916.05 03/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711794
Principal investigator 1 Boehringer Ingelheim International GmbH $1,008.80 03/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711796
Principal investigator 1 Boehringer Ingelheim International GmbH $8.10 03/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711798
Principal investigator 1 Boehringer Ingelheim International GmbH $87.60 03/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711800
Principal investigator 1 Boehringer Ingelheim International GmbH $1,540.00 03/24/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709128
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 03/24/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709146
Principal investigator 1 Boehringer Ingelheim International GmbH $539.00 03/24/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709152
Principal investigator 1 Boehringer Ingelheim International GmbH $280.00 03/24/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709156
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 03/24/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709166
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709110
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709112
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709114
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709116
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709118
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709120
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709122
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709124
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709126
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709130
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709132
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709134
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709136
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709138
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709140
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709142
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709144
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709148
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709150
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709154
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709158
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709160
Principal investigator 1 Boehringer Ingelheim International GmbH $30.80 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709162
Principal investigator 1 Boehringer Ingelheim International GmbH $82.60 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709164
Principal investigator 1 Boehringer Ingelheim International GmbH $135.80 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709168
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709170
Principal investigator 1 Boehringer Ingelheim International GmbH $140.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709172
Principal investigator 1 Boehringer Ingelheim International GmbH $145.60 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709174
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711740
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711742
Principal investigator 1 Boehringer Ingelheim International GmbH $4,480.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711744
Principal investigator 1 Boehringer Ingelheim International GmbH $8,680.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711746
Principal investigator 1 Boehringer Ingelheim International GmbH $315.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711748
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711750
Principal investigator 1 Boehringer Ingelheim International GmbH $4,480.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711752
Principal investigator 1 Boehringer Ingelheim International GmbH $17,360.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711754
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711786
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 03/19/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711788
Principal investigator 1 Boehringer Ingelheim International GmbH $847.00 03/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711584
Principal investigator 1 Boehringer Ingelheim International GmbH $847.00 03/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711586
Principal investigator 1 Boehringer Ingelheim International GmbH $482.00 03/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711722
Principal investigator 1 Boehringer Ingelheim International GmbH $1,120.00 03/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711724
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 03/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711726
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 03/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711728
Principal investigator 1 Boehringer Ingelheim International GmbH $4,480.00 03/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711730
Principal investigator 1 Boehringer Ingelheim International GmbH $8,680.00 03/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711732
Principal investigator 1 Boehringer Ingelheim International GmbH $2,410.00 03/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711734
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 03/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711736
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 03/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711738
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 03/12/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711784
Principal investigator 1 Boehringer Ingelheim International GmbH $63.34 03/11/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711608
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711620
Principal investigator 1 Boehringer Ingelheim International GmbH $70.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711622
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711624
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711626
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711628
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711630
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711632
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711634
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711636
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711638
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711640
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711642
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711644
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711646
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711648
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711650
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711652
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711654
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711656
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711658
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711660
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711662
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711664
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711666
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711668
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711670
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711672
Principal investigator 1 Boehringer Ingelheim International GmbH $4,778.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711674
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711676
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711678
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711680
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711682
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711684
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711686
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711688
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711690
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711692
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711694
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711696
Principal investigator 1 Boehringer Ingelheim International GmbH $4,778.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711698
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711700
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711702
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711704
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711706
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711708
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711710
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711712
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711714
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711716
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711718
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 03/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711720
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 03/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709208
Principal investigator 1 Boehringer Ingelheim International GmbH $175.00 03/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709226
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 03/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709228
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711570
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711572
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711574
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711576
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711578
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711580
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 02/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711600
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 02/28/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711602
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 02/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709178
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 02/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709180
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 02/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709906
Principal investigator 1 Boehringer Ingelheim International GmbH $71.54 02/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711790
Principal investigator 1 Boehringer Ingelheim International GmbH $584.00 02/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711810
Principal investigator 1 Boehringer Ingelheim International GmbH $3.24 02/25/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711812
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 02/10/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711484
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 02/10/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711486
Principal investigator 1 Boehringer Ingelheim International GmbH $462.00 02/10/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711494
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 02/10/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711496
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 02/10/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711532
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 02/10/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711534
Principal investigator 1 Boehringer Ingelheim International GmbH $8,960.00 02/10/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711536
Principal investigator 1 Boehringer Ingelheim International GmbH $17,360.00 02/10/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711538
Principal investigator 1 Boehringer Ingelheim International GmbH $482.00 02/10/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711540
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 02/10/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711542
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 02/10/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711544
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 02/10/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711546
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 02/10/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711548
Principal investigator 1 Boehringer Ingelheim International GmbH $482.00 02/10/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711550
Principal investigator 1 Boehringer Ingelheim International GmbH $8,960.00 02/10/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711552
Principal investigator 1 Boehringer Ingelheim International GmbH $17,360.00 02/10/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711554
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711482
Principal investigator 1 Boehringer Ingelheim International GmbH $924.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711488
Principal investigator 1 Boehringer Ingelheim International GmbH $462.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711490
Principal investigator 1 Boehringer Ingelheim International GmbH $308.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711492
Principal investigator 1 Boehringer Ingelheim International GmbH $525.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711498
Principal investigator 1 Boehringer Ingelheim International GmbH $3,750.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711500
Principal investigator 1 Boehringer Ingelheim International GmbH $8,960.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711502
Principal investigator 1 Boehringer Ingelheim International GmbH $26,040.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711504
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711506
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711508
Principal investigator 1 Boehringer Ingelheim International GmbH $482.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711510
Principal investigator 1 Boehringer Ingelheim International GmbH $1,120.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711512
Principal investigator 1 Boehringer Ingelheim International GmbH $1,456.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711514
Principal investigator 1 Boehringer Ingelheim International GmbH $1,446.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711516
Principal investigator 1 Boehringer Ingelheim International GmbH $280.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711518
Principal investigator 1 Boehringer Ingelheim International GmbH $1,092.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711520
Principal investigator 1 Boehringer Ingelheim International GmbH $482.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711522
Principal investigator 1 Boehringer Ingelheim International GmbH $280.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711524
Principal investigator 1 Boehringer Ingelheim International GmbH $182.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711526
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711528
Principal investigator 1 Boehringer Ingelheim International GmbH $46.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711530
Principal investigator 1 Boehringer Ingelheim International GmbH $60.00 02/05/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711556
Principal investigator 1 Boehringer Ingelheim International GmbH $8,000.00 02/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709104
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 02/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709106
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 02/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709108
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 02/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709900
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 02/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709902
Principal investigator 1 Boehringer Ingelheim International GmbH $8,000.00 02/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220709904
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 02/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709594
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711558
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711560
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711562
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711564
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711566
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711568
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 01/31/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711594
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 01/31/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711596
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 01/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709176
Principal investigator 1 Boehringer Ingelheim International GmbH $964.00 01/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711056
Principal investigator 1 Boehringer Ingelheim International GmbH $560.00 01/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711058
Principal investigator 1 Boehringer Ingelheim International GmbH $364.00 01/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711060
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 01/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711062
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 01/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711064
Principal investigator 1 Boehringer Ingelheim International GmbH $8,960.00 01/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711066
Principal investigator 1 Boehringer Ingelheim International GmbH $17,360.00 01/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711068
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 01/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711310
Principal investigator 1 Boehringer Ingelheim International GmbH $462.00 01/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711318
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 01/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711320
Principal investigator 1 Boehringer Ingelheim International GmbH $1,095.00 01/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711802
Principal investigator 1 Boehringer Ingelheim International GmbH $1,008.80 01/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711804
Principal investigator 1 Boehringer Ingelheim International GmbH $10.80 01/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711806
Principal investigator 1 Boehringer Ingelheim International GmbH $58.40 01/27/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711808
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711034
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711036
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711038
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711040
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711042
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711044
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711046
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711048
Principal investigator 1 Boehringer Ingelheim International GmbH $1,333.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711050
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711052
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711054
Principal investigator 1 Boehringer Ingelheim International GmbH $1,722.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711070
Principal investigator 1 Boehringer Ingelheim International GmbH $1,722.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711072
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711074
Principal investigator 1 Boehringer Ingelheim International GmbH $1,722.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711076
Principal investigator 1 Boehringer Ingelheim International GmbH $1,722.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711078
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711080
Principal investigator 1 Boehringer Ingelheim International GmbH $497.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711082
Principal investigator 1 Boehringer Ingelheim International GmbH $1,722.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711084
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711086
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711088
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711090
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711092
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711094
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711096
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711098
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711100
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711102
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711104
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711106
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711108
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711110
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711112
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711114
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711116
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711118
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711120
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711122
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711124
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711126
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711128
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711130
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711132
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711134
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711136
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711138
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711140
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711142
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711144
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711146
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711148
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711150
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711152
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711154
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711156
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711158
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711160
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711162
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711164
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711166
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711168
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711170
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711172
Principal investigator 1 Boehringer Ingelheim International GmbH $4,778.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711174
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711176
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711178
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711180
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711182
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711184
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711186
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711188
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711190
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711192
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711194
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711196
Principal investigator 1 Boehringer Ingelheim International GmbH $1,827.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711198
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711200
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711202
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711204
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711206
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711208
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711210
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711212
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711214
Principal investigator 1 Boehringer Ingelheim International GmbH $4,061.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711216
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711218
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711220
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711222
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711224
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711226
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711228
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711230
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711232
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711234
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711236
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711238
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711240
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711242
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711244
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711246
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711248
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711250
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711252
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711254
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711256
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711258
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711260
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711262
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711264
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711266
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711268
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711270
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711272
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711274
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711276
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711278
Principal investigator 1 Boehringer Ingelheim International GmbH $3,998.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711280
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711282
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711284
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711286
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711288
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711290
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711292
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711294
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711296
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711298
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711300
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711302
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711304
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711306
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711308
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711326
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711328
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711330
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711332
Principal investigator 1 Boehringer Ingelheim International GmbH $4,778.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711334
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711336
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711338
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711340
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711342
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711344
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711346
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711348
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711350
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711352
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711354
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711356
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711358
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711360
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711362
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711364
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711366
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711368
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711370
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711372
Principal investigator 1 Boehringer Ingelheim International GmbH $980.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711408
Principal investigator 1 Boehringer Ingelheim International GmbH $497.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711410
Principal investigator 1 Boehringer Ingelheim International GmbH $497.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711412
Principal investigator 1 Boehringer Ingelheim International GmbH $497.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711414
Principal investigator 1 Boehringer Ingelheim International GmbH $497.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711416
Principal investigator 1 Boehringer Ingelheim International GmbH $1,722.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711418
Principal investigator 1 Boehringer Ingelheim International GmbH $1,722.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711420
Principal investigator 1 Boehringer Ingelheim International GmbH $2,968.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711422
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711424
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711426
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711428
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711430
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711432
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711434
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711436
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711438
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711440
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711442
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711444
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711446
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711448
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711450
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711452
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711454
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711456
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711458
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711460
Principal investigator 1 Boehringer Ingelheim International GmbH $3,104.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711462
Principal investigator 1 Boehringer Ingelheim International GmbH $3,069.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711464
Principal investigator 1 Boehringer Ingelheim International GmbH $3,318.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711466
Principal investigator 1 Boehringer Ingelheim International GmbH $3,556.00 01/15/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711468
Principal investigator 1 Boehringer Ingelheim International GmbH $63.34 01/07/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711598
Principal investigator 1 Boehringer Ingelheim International GmbH $462.00 01/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711316
Principal investigator 1 Boehringer Ingelheim International GmbH $964.00 01/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711390
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 01/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711392
Principal investigator 1 Boehringer Ingelheim International GmbH $1,092.00 01/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711394
Principal investigator 1 Boehringer Ingelheim International GmbH $105.00 01/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711396
Principal investigator 1 Boehringer Ingelheim International GmbH $46.00 01/06/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711398
Principal investigator 1 Boehringer Ingelheim International GmbH $539.00 01/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711312
Principal investigator 1 Boehringer Ingelheim International GmbH $616.00 01/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711314
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 01/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711322
Principal investigator 1 Boehringer Ingelheim International GmbH $46.00 01/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711324
Principal investigator 1 Boehringer Ingelheim International GmbH $1,928.00 01/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711374
Principal investigator 1 Boehringer Ingelheim International GmbH $420.00 01/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711376
Principal investigator 1 Boehringer Ingelheim International GmbH $182.00 01/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711378
Principal investigator 1 Boehringer Ingelheim International GmbH $2,892.00 01/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711380
Principal investigator 1 Boehringer Ingelheim International GmbH $560.00 01/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711382
Principal investigator 1 Boehringer Ingelheim International GmbH $364.00 01/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711384
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 01/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711386
Principal investigator 1 Boehringer Ingelheim International GmbH $46.00 01/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711388
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 01/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711400
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 01/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711402
Principal investigator 1 Boehringer Ingelheim International GmbH $4,480.00 01/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711404
Principal investigator 1 Boehringer Ingelheim International GmbH $8,680.00 01/03/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711406
Principal investigator 1 Boehringer Ingelheim International GmbH $50.00 01/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709094
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 01/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709096
Principal investigator 1 Boehringer Ingelheim International GmbH $75.00 01/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709098
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 01/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709100
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 01/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220709102
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711470
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711472
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711474
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711476
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711478
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Covenant Metabolic Specialists-Fort Myers
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220711480